Malaysia vs Tunisia: Average cost of drugs for extensively drug-resistant tuberculosis
Malaysia
10,000 constant 2022 US$
in 2024
Tunisia
40,560 constant 2022 US$
in 2023
Malaysia rank
4th
Tunisia rank
1st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Malaysia
- Tunisia
How they compare
Tunisia currently reports 40,560 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia, a difference of 30,560 constant 2022 US$.
That makes Tunisia's figure about 4.1 times Malaysia's.
The two have swapped places 1 time across 6 shared years of data; in 2017 it was Malaysia ahead.
Malaysia ranks 4th and Tunisia ranks 1st of 56 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malaysia | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 45,000 constant 2022 US$ | 7,000 constant 2022 US$ | 38,000 constant 2022 US$ | Malaysia |
| 2020s | 25,000 constant 2022 US$ | 20,440 constant 2022 US$ | 4,560 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Malaysia or Tunisia?
- Tunisia, at 40,560 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Malaysia and Tunisia?
- 30,560 constant 2022 US$, with Tunisia ahead.
- How many years of comparable data are there for Malaysia and Tunisia?
- 6 years are reported by both, from 2017 to 2023.
- How do Malaysia and Tunisia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Malaysia ranks 4th and Tunisia ranks 1st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.